Literature DB >> 30565983

Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?

Andrew P Ambrosy1,2, Craig S Parzynski3, Daniel J Friedman4,5, Marat Fudim4,5, Adrian F Hernandez4,5, Gregg C Fonarow6, Frederick A Masoudi7, Sana M Al-Khatib4,5.   

Abstract

BACKGROUND: Landmark studies have demonstrated the safety and efficacy of implantable cardioverter-defibrillators (ICDs) in selected stable ambulatory patients with heart failure (HF) with a reduced ejection fraction receiving optimal medical therapy. It is not known whether a recent hospitalization for HF before ICD placement is associated with subsequent outcomes.
METHODS: A post hoc analysis was performed of Medicare beneficiaries enrolled in the National Cardiovascular Data Registry's ICD Registry with a known diagnosis of HF and an ejection fraction ≤35% underdoing a new ICD placement for primary prevention. Patients were grouped based on the timing of ICD placement from the last hospitalization for HF. The association between timing of ICD placement and outcomes was assessed by using multivariable logistic regression models.
RESULTS: The final analytic cohort included 81 180 patients undergoing initial ICD placement for primary prevention who were currently hospitalized for HF (n=11 563, 14%), hospitalized for HF within 3 months (n=6252, 8%), or hospitalized for HF >3 months previously or had no previous hospitalizations for HF (n=63 365, 78%). Patients currently or recently hospitalized for HF had a higher unadjusted composite periprocedural complication rate (2.60% versus 1.71% versus 1.25%, P<0.001). After adjusting for potential confounders, patients currently hospitalized for HF were at higher risk for death (odds ratio, 2.25; 95% CI, 2.02-2.52; P <0.001) and all-cause readmission (odds ratio, 1.89; 95% CI, 1.79-1.99; P <0.001) at 90 days.
CONCLUSION: Older patients currently or recently hospitalized for HF undergoing initial ICD placement for primary prevention experienced a higher rate of periprocedural complications and were at increased risk of death in comparison with those receiving an ICD without recent HF hospitalization. Additional prospective, real-world, pragmatic, comparative effectiveness studies should be conducted to define the optimal timing of ICD placement.

Entities:  

Keywords:  defibrillators, implantable; heart failure; hospitalization; treatment outcome

Mesh:

Substances:

Year:  2018        PMID: 30565983      PMCID: PMC6931009          DOI: 10.1161/CIRCULATIONAHA.118.035627

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 2.  The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011.

Authors:  Mark S Kremers; Stephen C Hammill; Charles I Berul; Christina Koutras; Jeptha S Curtis; Yongfei Wang; Jim Beachy; Laura Blum Meisnere; Del M Conyers; Matthew R Reynolds; Paul A Heidenreich; Sana M Al-Khatib; Ileana L Pina; Kathleen Blake; Mary Norine Walsh; Bruce L Wilkoff; Alaa Shalaby; Frederick A Masoudi; John Rumsfeld
Journal:  Heart Rhythm       Date:  2013-02-09       Impact factor: 6.343

3.  Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

Authors:  Christopher M O'Connor; Alan B Miller; John E A Blair; Marvin A Konstam; Patricia Wedge; Maria C Bahit; Peter Carson; Markus Haass; Paul J Hauptman; Marco Metra; Ron M Oren; Richard Patten; Ileana Piña; Sherryn Roth; Jonathan D Sackner-Bernstein; Brian Traver; Thomas Cook; Mihai Gheorghiade
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

4.  Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry).

Authors:  John A Dodson; Matthew R Reynolds; Haikun Bao; Sana M Al-Khatib; Eric D Peterson; Mark S Kremers; Michael J Mirro; Jeptha P Curtis
Journal:  J Am Coll Cardiol       Date:  2013-12-11       Impact factor: 24.094

5.  Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.

Authors:  Benjamin A Steinberg; Xin Zhao; Paul A Heidenreich; Eric D Peterson; Deepak L Bhatt; Christopher P Cannon; Adrian F Hernandez; Gregg C Fonarow
Journal:  Circulation       Date:  2012-05-21       Impact factor: 29.690

6.  Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries.

Authors:  Chih-Ying Chen; Lynne Warner Stevenson; Garrick C Stewart; John D Seeger; Lauren Williams; Jessica J Jalbert; Soko Setoguchi
Journal:  J Am Coll Cardiol       Date:  2013-03-26       Impact factor: 24.094

7.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Authors:  Mihai Gheorghiade; Marvin A Konstam; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

8.  Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.

Authors:  Sean D Pokorney; Sana M Al-Khatib; Jie-Lena Sun; Phillip Schulte; Christopher M O'Connor; John R Teerlink; Paul W Armstrong; Justin A Ezekowitz; Randall C Starling; Adriaan A Voors; Eric J Velazquez; Adrian F Hernandez; Robert J Mentz
Journal:  Eur J Heart Fail       Date:  2017-12-20       Impact factor: 15.534

9.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

10.  Declining Risk of Sudden Death in Heart Failure.

Authors:  Li Shen; Pardeep S Jhund; Mark C Petrie; Brian L Claggett; Simona Barlera; John G F Cleland; Henry J Dargie; Christopher B Granger; John Kjekshus; Lars Køber; Roberto Latini; Aldo P Maggioni; Milton Packer; Bertram Pitt; Scott D Solomon; Karl Swedberg; Luigi Tavazzi; John Wikstrand; Faiez Zannad; Michael R Zile; John J V McMurray
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

View more
  1 in total

Review 1.  Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use.

Authors:  Faisal M Merchant; Wayne C Levy; Daniel B Kramer
Journal:  J Am Heart Assoc       Date:  2020-02-24       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.